Syphilis Screening - Nontreponemal (RPR)
A special account is required to order pre-transplant testing. Contact Client Services or your account executive to set up a pre-transplant account to order this assay. Specimens should not be collected until after account has been created.
The ASI Automated RPR (rapid plasma reagin) Test For Syphilis for use on the ASI Evolution, is a qualitative nontreponemal flocculation test for the detection of reagin antibodies in human serum and plasma as a screening test for serological evidence of syphilis.
The ASI Evolution is intended to be used as a fully automated analyzer to objectively interpret the results of the ASI Automated RPR Test For Syphilis. The ASI Evolution is designed to provide standardized test interpretation and to provide for storage, retrieval, and transmittal of the test results.
The ASI Automated RPR Test For Syphilis for use on the ASI Evolution is for professional use only. The test is intended to be used for blood donor screening and for cadaveric (non-heart beating) donor specimens for tissue donation. This test is not intended for diagnostic use.
About Syphilis
Treponema pallidum, the etiological agent of syphilis, induces the production of at least two types of antibodies in human infection: anti-treponemal antibodies that can be detected by FTA-ABS antigen1, and anti-nontreponemal antibodies (reagin) that can be detected by RPR antigen2.
ProcedureThe ASI Automated RPR Test for Syphilis for use on the ASI Evolution is an automated macroscopic nontreponemal flocculation test to be used for the detection of reagin. This test kit is intended to be used with the ASI Evolution Automated Syphilis Analyzer. The ASI Evolution instrument automates the dispensing of serum or plasma samples and the dispensing of carbon antigen reagent. The microparticulate carbon RPR antigen enhances the visual discrimination between reactive and nonreactive results. The reagin-type antibody binds with the antigen that is composed of a complex of cardiolipin, lecithin and cholesterol particles with activated charcoal. The result of this antigen-antibody reaction is macroscopic flocculation. The ASI Evolution uses and internal camera an image processing algorithm to read the RPR agglutination reaction and report a reactive or non-reactive result.
Test performed by Eurofins DPT, 6933 S. Revere Parkway, Centennial, CO 80112. This test has been cleared or approved for diagnostic use by the U.S. Food and Drug Administration.
Within 24 hours from receipt of specimen.
Specimen Type | Order Code | CPT Code | NY Approved | Volume | Assay Range | Special Instructions |
---|---|---|---|---|---|---|
Plasma (1) | 30806 | 86592 | Yes | 200 µL (100 µL min.) |
Qualitative |
|
Serum (1) | 30806 | 86592 | Yes | 200 µL (100 µL min.) |
Qualitative |
|
All specimens must be labeled with patient's name and collection date. A Eurofins Viracor/DPT Pre-Transplant test requisition form must accompany each specimen. Multiple tests can be run on one specimen. Ship specimens FedEx Priority Overnight® to: Eurofins DPT, 6933 S. Revere Parkway, Centennial, CO 80112.
Causes for RejectionWhole blood frozen, plasma samples frozen, specimens beyond their acceptable length of time from collection as listed in the specimen handling, or specimen types other than those listed.
Specimens are approved for testing in New York only when indicated in the Specimen Information field above. The CPT codes provided are based on Eurofins DPT's interpretation of the American Medical Association's Current Procedural Terminology (CPT) codes and are provided for informational purposes only. CPT coding is the sole responsibility of the billing party. Questions regarding coding should be addressed to your local Medicare carrier. Eurofins DPT assumes no responsibility for billing errors due to reliance on the CPT codes illustrated in this material.
References1. Hunter EF, Deacon WE, Myer PE. 1964. Public Health Reports, 79:410-412.
2. Larsen SA, Hunter EF, Kraus SJ (ed.). 1990. Manual of Tests for Syphilis, Public Health Service, Washington, D.C.